<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758016</url>
  </required_header>
  <id_info>
    <org_study_id>2304-2000-RMB CTIL</org_study_id>
    <nct_id>NCT01758016</nct_id>
  </id_info>
  <brief_title>Haptoglobin and Diabetes Complications in Pregnancy</brief_title>
  <official_title>Haptoglobin and Diabetes Complications in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnancies of patients with Diabetes are associated with increase adverse pregnancy outcome
      . The risk for vascular complications including: Intra uterine growth restriction (20%),
      hypertension (31%), preeclampsia (15%), eclampsia and placental abruption are significantly
      greater than those in background populations. The risk of developing vascular complications
      in diabetes pregnancies although is correlated with  the severity and length of the disease
      is not fully understood. Enhanced oxidation  has been suggested to be the underlying
      abnormality responsible for some of the complications of diabetes.

      Haptoglobin (Hp) is an abundant plasma glycoprotein produced in the liver. The best
      understood function of Hp is to bind free hemoglobin (Hb) released from red blood cells.
      Extracorpuscular Hb is a potent Fenton reagent.capable of of inflicting oxidative tissue
      damage. Hp binds to Hb and serves to inhibit the oxidative potential of Hb by preventing the
      release of heme iron.

      The haptoglobin (Hp) gene at chromosomal locus 16q22 is polymorphic, with two common alleles
      denoted 1 and 2.  the prevalence of Hp 1-1, Hp 1-2 and Hp 2-2 genotypes is approximately
      16%, 48% and 36%, respectively. In the western world. A total  of five independent
      longitudinal studies have demonstrated that DM individuals with Hp 2-2 genotype have a two
      to five-fold increased risk of CVD as compared to DM individuals without the Hp 2-2 genotype
      We sought to determine whether HP genotype plays important role in development of vascular
      complications in pregastational pregnancies. and whether Hp genotype 2-2  is a risk factor
      for developing gestational diabetes (GDM)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>vascular complications in pregnancy</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Diabetes in Pregnancy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Pregastetional diabetic patients currently pregnant

          2. Gestational diabetes patients currently pregnant
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes in pregnancy

        Exclusion Criteria:

          -  Not willing to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ron beloosesky, M.D</last_name>
    <phone>011972509205759</phone>
    <email>tomor2304@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva`</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer beharier, M.D</last_name>
      <phone>001972525398676</phone>
      <email>oferbeharie@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ofer Beharie, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eyal Sheiner, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Cmpus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ron Beloosesky, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nizzar KHATIB, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Hospital</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tal Biron-Shental, M.D</last_name>
      <phone>011972528362331</phone>
      <email>Tal.Biron-Shental@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Tal Biron-Shental, M/D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 30, 2012</lastchanged_date>
  <firstreceived_date>December 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
